Table 4 Adjuvant medical therapy, MACCE and access site complications in women and men ≥ 70 years
Women | Men | P-value | ||
|---|---|---|---|---|
Medical therapy during PCI | ||||
Heparin (%) | Total | 85.5 | 84.8 | 0.160 |
STEMI | 90.7 | 91.0 | 0.710 | |
NSTEMI | 85.2 | 84.0 | 0.184 | |
stable CAD | 83.8 | 83.4 | 0.606 | |
LMW-Heparin (%) | Total | 3.4 | 3.7 | 0.211 |
STEMI | 4.9 | 4.4 | 0.461 | |
NSTEMI | 5.7 | 6.7 | 0.080 | |
stable CAD | 1.5 | 1.9 | 0.065 | |
Bivalirudin (%) | Total | 0.5 | 0.6 | 0.281 |
STEMI | 0.4 | 0.4 | 0.730 | |
NSTEMI | 0.9 | 0.8 | 0.893 | |
stable CAD | 0.4 | 0.6 | 0.113 | |
ASA i.v. (%) | Total | 43.9 | 41.6 | <0.001 |
STEMI | 66.0 | 67.1 | 0.434 | |
NSTEMI | 42.1 | 39.3 | 0.025 | |
stable CAD | 36.9 | 35.4 | 0.093 | |
ASA oral (%) | Total | 62.2 | 63.7 | 0.019 |
STEMI | 46.1 | 47.7 | 0.313 | |
NSTEMI | 65.0 | 65.2 | 0.834 | |
stable CAD | 66.3 | 67.5 | 0.169 | |
Clopidogrel (%) | Total | 88.5 | 88.4 | 0.880 |
STEMI | 91.7 | 92.1 | 0.678 | |
NSTEMI | 90.8 | 90.6 | 0.832 | |
stable CAD | 86.0 | 86.3 | 0.647 | |
GPIIb/IIIa-Inhibitor (%) | Total | 21.8 | 21.5 | 0.645 |
STEMI | 57.4 | 59.7 | 0.085 | |
NSTEMI | 26.1 | 27.3 | 0.171 | |
stable CAD | 7.1 | 8.3 | 0.002 | |
Procedure related mortality and MACCE | ||||
Mortality (intrahospital) (%) | Total | 2.8 | 2.2 | 0.006 |
STEMI | 9.4 | 8.4 | 0.251 | |
NSTEMI | 2.9 | 2.7 | 0.686 | |
stable CAD | 0.6 | 0.3 | 0.013 | |
MACCE (Death, MI, Stroke/TIA) (%) | Total | 3.3 | 2.8 | 0.023 |
STEMI | 10.2 | 9.3 | 0.399 | |
NSTEMI | 3.5 | 3.2 | 0.452 | |
stable CAD | 1.2 | 0.8 | 0.031 | |
Non-MACCE access site related complications (i.e. bleeding) (%) | Total | 3.6 | 1.8 | <0.001 |
STEMI | 4.2 | 1.3 | <0.001 | |
NSTEMI | 4.0 | 2.1 | <0.001 | |
stable CAD | 3.3 | 1.8 | <0.001 | |